Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer

  • Takehiro Shiraishi
  • Eiji ShintoEmail author
  • Satsuki Mochizuki
  • Hitoshi Tsuda
  • Yoshiki Kajiwara
  • Koichi Okamoto
  • Takahiro Einama
  • Kazuo Hase
  • Hideki Ueno
Original Article


Mesothelin (MSLN) is a cell-surface glycoprotein present on mesothelial cells and in many cancers, where expression is generally associated with an unfavorable prognosis. The clinical significance and pathological characteristics of MSLN expression were evaluated by immunohistochemical staining of tissues from 530 stage ΙΙ/ΙΙΙ colorectal cancer (CRC) patients with R0 resection. Eighty-eight (16.6%) were MSLN-positive; 33 (37.5%) showed a luminal staining pattern whereas 55 (62.5%) showed a non-luminal staining pattern. MSLN expression, including the luminal and non-luminal staining patterns, was associated with shorter cancer-specific survival (CSS) period in stage ΙΙ (n = 314, P = 0.024) and stage ΙΙΙ (n = 216, P = 0.0002) CRC patients. The non-luminal staining pattern was correlated with poor prognosis in stage ΙΙ (P = 0.0006) and III (P < 0.0001) CRC, but a luminal staining pattern was not significantly correlated with prognosis. Cox’s multivariate analysis revealed that a non-luminal staining pattern was associated with CSS independently of other conventional parameters in stage II (P = 0.040, hazard ratio (HR) = 2.92) and III (P = 0.020, HR = 2.13) CRC patients. Immunohistochemical evaluation of MSLN expression was helpful in the prediction of patient prognosis in stage II/III CRC.


Colorectal cancer Mesothelin Glycoprotein Immunohistochemistry Prognosis 



Confidence interval


Cancer-specific survival


Epidermal growth factor receptor


Hazard ratio


Receiver operating characteristic


Serial analysis of gene expression


Authors’ contributions

TS and ES conceived and designed the experiments. TS and SM performed the experiments. TS, ES, and HT analyzed histopathological data. TS and ES drafted the manuscript. HT, YK, KO, KH, and HU revised the manuscript. TS finalized the manuscript. All authors reviewed and approved the manuscript.

Compliance with ethical standards

The experiments reported here were carried out in agreements with the Declaration of Helsinki principles and in agreement with the Ethics Committee of the National Defense Medical College Hospital, Tokorozawa, Japan.

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29. CrossRefGoogle Scholar
  2. 2.
    Kotake K, Honjo S, Sugihara K, Kato T, Kodaira S, Takahashi T, Yasutomi M, Muto T, Koyama Y (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46:S32–S43. Google Scholar
  3. 3.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947. CrossRefGoogle Scholar
  4. 4.
    Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047. CrossRefGoogle Scholar
  5. 5.
    Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671. CrossRefGoogle Scholar
  6. 6.
    Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. CrossRefGoogle Scholar
  7. 7.
    Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93:136–140. CrossRefGoogle Scholar
  8. 8.
    Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373–381. CrossRefGoogle Scholar
  9. 9.
    Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy, Clinical cancer research. Clin Cancer Res 10:3937–3942. CrossRefGoogle Scholar
  10. 10.
    Ordonez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192–197. CrossRefGoogle Scholar
  11. 11.
    Ordonez NG (2003) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27:1418–1428CrossRefGoogle Scholar
  12. 12.
    Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM (2003) Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34:605–609. CrossRefGoogle Scholar
  13. 13.
    Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862–3868Google Scholar
  14. 14.
    Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13:243–247. CrossRefGoogle Scholar
  15. 15.
    Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195–199. CrossRefGoogle Scholar
  16. 16.
    Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, Tanaka S, Nishihara H, Taketomi A, Todo S (2012) Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107:137–142. CrossRefGoogle Scholar
  17. 17.
    Illei PB, Alewine C, Zahurak M, Cowan ML, Montgomery E, Hassan R, Xiang L, Pastan I, Kelly RJ (2016) Mesothelin expression in advanced gastroesophageal cancer represents a novel target for immunotherapy. Appl Immunohistochem Mol Morphol 24:246–252. CrossRefGoogle Scholar
  18. 18.
    Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, Wang J, Canto M, Eshleman JR, Montgomery EA, Maitra A (2008) Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine 4:295–301. CrossRefGoogle Scholar
  19. 19.
    Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M, Rusch VW, Adusumilli PS (2012) Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s associated esophageal adenocarcinoma. Cancer Epidemiol Biomark Prev 21:482–486. CrossRefGoogle Scholar
  20. 20.
    Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I (2016) Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 34:4171–4179. CrossRefGoogle Scholar
  21. 21.
    Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15:5274–5279. CrossRefGoogle Scholar
  22. 22.
    Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132–6138. CrossRefGoogle Scholar
  23. 23.
    Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149. CrossRefGoogle Scholar
  24. 24.
    Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11:6342–6351. CrossRefGoogle Scholar
  25. 25.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112–120. CrossRefGoogle Scholar
  26. 26.
    Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q (2008) Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 7:286–296. CrossRefGoogle Scholar
  27. 27.
    Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours, 8th edn. Wiley-Liss, New YorkGoogle Scholar
  28. 28.
    Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the C, Rectum (2015) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207–239. CrossRefGoogle Scholar
  29. 29.
    Shinto E, Tsuda H, Ueno H, Hashiguchi Y, Hase K, Tamai S, Mochizuki H, Inazawa J, Matsubara O (2005) Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal cancers, disclosed by area-specific four-point tissue microarrays. Lab Investig 85:257–266. CrossRefGoogle Scholar
  30. 30.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefGoogle Scholar
  31. 31.
    Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, Orntoft TF (2002) Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer 95:2422–2430. CrossRefGoogle Scholar
  32. 32.
    Fukazawa S, Shinto E, Tsuda H, Ueno H, Shikina A, Kajiwara Y, Yamamoto J, Hase K (2015) Laminin beta3 expression as a prognostic factor and a predictive marker of chemoresistance in colorectal cancer. Jpn J Clin Oncol 45:533–540. Google Scholar
  33. 33.
    Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih Ie M (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12:827–831. CrossRefGoogle Scholar
  34. 34.
    Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, Hsieh CY, Chen CA (2009) High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 100:1144–1153. CrossRefGoogle Scholar
  35. 35.
    Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, Takahashi N, Kamiyama T, Nishihara H, Taketomi A, Todo S (2014) C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol 49:81–92. CrossRefGoogle Scholar
  36. 36.
    Bharadwaj U, Li M, Chen C, Yao Q (2008) Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 6:1755–1765. CrossRefGoogle Scholar
  37. 37.
    Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q (2011) Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32:1013–1024. CrossRefGoogle Scholar
  38. 38.
    Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190–9198. CrossRefGoogle Scholar
  39. 39.
    Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5(50):50. CrossRefGoogle Scholar
  40. 40.
    Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, Yamaue H (2012) Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 103:739–746. CrossRefGoogle Scholar
  41. 41.
    Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M (2009) A binding domain on mesothelin for CA125/MUC16. J Biol Chem 284:3739–3749. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Takehiro Shiraishi
    • 1
  • Eiji Shinto
    • 1
    Email author
  • Satsuki Mochizuki
    • 1
  • Hitoshi Tsuda
    • 2
  • Yoshiki Kajiwara
    • 1
  • Koichi Okamoto
    • 1
  • Takahiro Einama
    • 1
  • Kazuo Hase
    • 1
  • Hideki Ueno
    • 1
  1. 1.Department of SurgeryNational Defense Medical CollegeSaitamaJapan
  2. 2.Department of Basic PathologyNational Defense Medical CollegeSaitamaJapan

Personalised recommendations